title: [Safer treatment with serum concentration monitoring of the new anticoagulants?].
authors.forename: Halvor
authors.initials: H
authors.lastname: Lundgaard
authors.forename: Roar
authors.initials: R
authors.lastname: Dyrkorn
authors.forename: Charlotte Lorentze
authors.initials: CL
authors.lastname: Stokes
authors.forename: Espen
authors.initials: E
authors.lastname: Molden
authors.forename: Olav
authors.initials: O
authors.lastname: Spigset
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects / Q000097:blood*; D000069604:Dabigatran / Q000009:adverse effects / Q000097:blood*; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring / Q000379:methods*; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D011720:Pyrazoles / Q000009:adverse effects / Q000097:blood*; D011728:Pyridones / Q000009:adverse effects / Q000097:blood*; D012015:Reference Standards; D012307:Risk Factors; D000069552:Rivaroxaban / Q000009:adverse effects / Q000097:blood*; D014812:Vitamin K / Q000037:antagonists & inhibitors
chemical_list: D000925:Anticoagulants; D011720:Pyrazoles; D011728:Pyridones; D014812:Vitamin K; C522181:apixaban; D000069552:Rivaroxaban; D000069604:Dabigatran